Core Viewpoint - Tevogen Bio has filed a new patent for its T cell vaccine, which utilizes its proprietary Tevogen.AI-powered PredicTcell technology to stimulate a T cell response, targeting the entire viral genome to mitigate mutation risks [1][2][8] Group 1: Vaccine Development - The T cell vaccine aims to provide a broader immune response by targeting the entire viral genome, similar to the lead product candidate TVGN 489, thus reducing the risk of mutations evading immune detection [2][8] - The development of this vaccine will not affect the previously announced topline forecasts of $1 billion each for Tevogen Bio Oncology and Specialty Care [3] Group 2: Strategic Focus - The current focus of the T cell vaccine development is on national security and protecting the U.S. military against biological threats, with potential for broader applications in the future [4] - The company emphasizes the importance of public trust and transparency throughout the vaccine development process [4] Group 3: Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops precision T cell therapies to address significant unmet needs in infectious diseases and cancers [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents [5][6]
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO